Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
Mylan (MYL) Misses Q3 EPS by 10c; Increases Low End of Guidance
November 6, 2017 7:05 AM ESTMylan (NASDAQ: MYL) reported Q3 EPS of $1.10, $0.10 worse than the analyst estimate of $1.20. Revenue for the quarter came in at $2.99 billion versus the consensus estimate of $3.1 billion.
Mylan is increasing the low end of our adjusted EPS guidance range, where we now expect to generate between $4.45 and $4.70 per share.
Mylan CEO Heather Bresch commented, "Our third quarter results, which included adjusted EPS of $1.10, were especially strong considering the ongoing challenges we experienced in the U.S., including accelerated deceleration of EpiPen sales - both from our launch of an authorized generic... More
